Printer Friendly

STI STRENGTHENS PRODUCT LINE, GLOBAL REACH TO BETTER POSITION FOR LONG-TERM GROWTH

 ROCKVILLE, Md., Jan. 21 /PRNewswire/ -- Survival Technology, Inc. (NASDAQ-NMS: STIQ) significantly strengthened its product line and global reach in fiscal 1992 to better position the company for long- term growth, STI President and Chief Executive Officer James H. Miller told shareholders at the company's annual meeting here. He noted that STI achieved its primary objectives of maintaining profitability, accelerating new product development and strengthening the corporate focus on its exclusive auto-injector technology.
 "Excluding military product sales associated with the Persian Gulf War," Miller said, "revenues increased 41 percent from $27.9 million in fiscal 1991 to $39.4 million for the fiscal year ended July 31, 1992." Sales of commercial products increased 64 percent over the prior year, and the company achieved earnings of $1.7 million (56 cents per share) in fiscal 1992. Despite the previously anticipated loss of military business in 1992, earnings performance was comparable to the previous year excluding tax loss carryforwards recorded in 1991.
 As recently announced, earnings in the first quarter of fiscal 1993 ended Oct. 31, 1992, were $606,000 (20 cents per share), an increase of 100 percent over the same period a year ago due to improved product mix through growth in sales of higher margin proprietary auto-injector products. Sales of EpiPen, a commercial auto-injector product produced by STI for allergic reactions, rose 113 percent in fiscal 1992 following expanded promotion.
 "A key step in building for the future was our acquisition of the assets of Medimech International, a U.K.-based producer of auto- injectors," Miller said. "This gives STI a European supply base for multinational pharmaceutical companies and adds important new technology to our product line."
 He pointed out, for example, that one of the auto-injector innovations acquired from Medimech can store compounds in dry form and mix them in solution prior to administration, which is essential for products unstable in solution. "This technology alone opens an estimated $180 million in additional market potential for auto- injectors," he said.
 STI is currently negotiating with a number of pharmaceutical and biotechnology companies for the development and production of new commercial products incorporating its auto-injector technology and other injection systems.
 An original development of STI, the auto-injector is a spring- loaded, pre-filled, pen-like device that allows the patient to inject medication in pre-measured doses quickly, safely, reliably and without seeing the needle. Potential new therapeutic areas for auto- injectors include analgesia, anemia, antiemetic, cardiology, diabetes, hormonal disorders, male sexual dysfunction, migraine and others.
 "EpiPen and military auto-injectors continue to be our principal auto-injector products at this time," Miller said, "but we anticipate that other pharmaceutical companies will recognize the merits of this technology and incorporate it into their products."
 The company also recently solidified its military business with the signing of an innovative contract with the U.S. Department of Defense designed to assure adequate supplies of nerve gas antidotes using the company's auto-injector delivery system. The contract is expected to generate $5-$6 million in annual revenue for STI, in addition to its military business with allied governments.
 "The company made important progress in 1992, and we enter 1993 with optimism," Miller said. "We are now able to more fully capitalize on STI's unique drug delivery technology and are increasingly well-positioned for long-term growth."
 STI is a technology-based health care company that designs, develops and produces automatic injectors, pre-filled syringes and medical electronics, with major focus on safe and convenient participation by the patient in injection therapy. The company also supplies delivery system design, pharmaceutical research and development and sterile product manufacturing to pharmaceutical companies worldwide.
 -0- 1/21/93
 /CONTACT: James H. Miller, president & CEO, or Jeffrey W. Church, vice president-finance & CFO, Survival Technology, 301-926-1800/
 (STIQ)


CO: Survival Technology, Inc. ST: Maryland IN: MTC SU:

DC -- DC007 -- 7304 01/21/93 10:23 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 21, 1993
Words:635
Previous Article:ETHYL REPORTS HIGHER 1992 RESULTS
Next Article:FORD PRICE INCREASE AVERAGES 0.4 PERCENT
Topics:


Related Articles
STI AND MYLAN ENTER AGREEMENT FOR PAIN MANAGEMENT PRODUCT
J. MILLER ASSUMES ADDITIONAL POST AS CHAIRMAN, PRESIDENT AND CEO OF BRUNSWICK BIOMEDICAL
GE SILICONES FORMS STRATEGIC ALLIANCE WITH STI FOR FIRESTOPPING PRODUCTS
STI REPORTS SECOND QUARTER EARNINGS INCREASE
STI INTERNATIONAL ENTERS AGREEMENT FOR NEW MILITARY AUTO-INJECTOR PRODUCT
SHARED TECHNOLOGIES FINALIZES ACQUISITION OF ACCESS TELECOMMUNICATION GROUP, L.P.
STI ANNOUNCES MAJORITY SHARES BUY-OUT TO FORM EXPANDED OPERATIONS
Superconductor Technologies Inc. Reports Fourth Quarter and Year-End 2002 Results.
Stockholders of Superconductor Technologies Inc. and Conductus, Inc. Approve Merger.
Markman Ruling Strengthens Positions Taken by Superconductor Technologies Inc. and Conductus, Inc. in ''215 Patent' Dispute, Companies Say.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters